Results 141 to 150 of about 64,045 (256)

The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis

open access: yesAdvanced Science, Volume 13, Issue 63, 12 November 2026.
Corramycin, a myxobacterial natural product antibiotic, exhibits potent bactericidal activity against multidrug‐resistant Mycobacterium tuberculosis. The compound hijacks bacterial transporters such as BacA and OppABCD to enter the cell and inhibits DNA synthesis through a previously unrecognized mode of DNA gyrase poisoning, locking the enzyme in an ...
Franziska Fries   +25 more
wiley   +1 more source

Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. [PDF]

open access: yesCell Rep Med
Wang R   +15 more
europepmc   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

open access: yesAdvanced Science, Volume 13, Issue 64, 16 November 2026.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu   +7 more
wiley   +1 more source

Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, HER2‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)–directed antibody–drug conjugate (ADC) with a topoisomerase I inhibitor payload and was approved by the Japan Pharmaceuticals and Medical Devices Agency in 2025 for patients with unresectable or recurrent hormone receptor–positive (HR+)/human epidermal
Hiroko Shimada   +18 more
wiley   +1 more source

Development of Novel Furan–Chalcone Derivatives as Targeting Bacterial DNA Gyrase and Topoisomerase IV: Design, Synthesis, and In Silico Studies

open access: yesChemistry &Biodiversity, Volume 23, Issue 11, November 2026.
Furan–chalcone derivatives (Na1–Na8) were successfully designed, synthesized, and biologically evaluated using integrated experimental and computational approaches. ABSTRACT A series of novel furan–chalcone derivatives (Na1–Na8) were synthesized and evaluated for their antimicrobial, antioxidant, DNA gyrase inhibitory, and computational properties ...
Nagaraj N Durgadasheemi, Vishal CS
wiley   +1 more source

Home - About - Disclaimer - Privacy